Thanks, conference our morning, Martin. Good and call. welcome to
in segments, quarter as sequential Animal as and Nutrition Health & the Human with EBITDA our another year-over-year earnings from achieved adjusted all delivered X modest We off sales, in for year record significant strong I record reporting & sales our the ongoing of fourth results financial our quarter pleased and segments. pleased sales We consolidated XXXX, Nutrition am which Health the and are growth Balchem. net Products with and Specialty of growth in very which adjusted for the segment. year-over-year capped of earnings, earnings fourth both quarter improvement operations delivered and fourth well particularly strength with
accomplishments full team detail past a Overall, more like over some Balchem the would to earnings year $XXX on the both quarter, significant into XXXX with reflect strong and in we Products for X.X% year Nutrition the the on sales for Specialty year, achieved compared minutes achieved Health strong Human the few Before We the to get another growing growth sales prior segments. and I Balchem. was million, record of year. of &
We from of of operations delivered EBITDA increase of increase million, XX.X% an $XXX year. from record earnings $XXX the an X.X% of record and million, prior also adjusted
of our further million In debt pay addition, on X.Xx. and to debt a our basis flow $XXX we allowing cash to us generated down free reduce strong leverage ratio net
also our made initiatives. good very strategic on progress We
launch growth. have our We enhanced innovate or continued new to products support and to
Human Nutrition & brought X to market. Our innovative products Health new segment
specialty a KXVITAL vitamin a which is microencapsulated first is patented from fermented, in fermentation DELTA form. The KX
VitaCholine our to our VitaCholine, second designed our healthier will nutrients the making of bioactive an multivitamins. health is cellular that The specifically a which is is folate third ingredient at which reduced Pro-Flo, for choline supports enriched existing is patented enhanced Optifolin+, all And formulation in of the offering These value vision existing customers, vitamins bring of life. a enable our to minerals, supporting more simultaneously add and stages to product place. while world launches and us of even inclusion
sustainability. addition cow is offers productivity products, Animal a & when and economically Health focused acid amino content lysine which reliably portfolio also a to and is meet great Animal AminoShure-XL, lysine bioavailability the requirements dairy designed Our on performance and considering of dairy lysine segment's lactating feed AminoShure-XL a product, consistently, Health encapsulated leading rumen-protected of and the Nutrition Nutrition segment to & newly-developed release next-generation cattle. stability, high-performing launched precision optimizing
brand market-leading some team. And also of building proud sports a VitaCholine, on of the NFL became partner professional brand We of KXVITAL, choline, progress for market-leading Jets, New awareness consumer the major market-leading team nutrient York made social essential market drive Balchem's further have Balchem's These on presence, of our a brands. to and and health. focus indeed specialty Munich brands. women's vitamin awareness for KX, with addition Bayern recently just partnerships, the media to awareness in increase women's our to partnered helping build our soccer increased is penetration drive the
pleased reduced significant compared In and tracking Goals progress Sustainability made already greenhouse withdrawal water usage reductions. our are our of our XX% emissions Balchem toward by We usage baseline, XXXX greenhouse we were also successfully out on water by emissions our gas substantial gas water report XXXX reduction XXXX, We that sixth to our in ahead reduce annual approximately on progress extremely objective. both in to to XXXX report goal XX%. showing sustainability XXXX
also advance several completed goal. of water reach XXXX to our in to the in so of We last within capital were important that next the collectively August or year year, us allow well projects designed goal usage
share, the continue operating objectives, and as time, X in December, lastly, increase And both once as remains world stakeholders. innovative Balchem's to the dividend, per taking of excellence double-digit health commitment growth to marked which our the dividend, we strategically needs our our Balchem. reinforced providing another in dividend the $X.XX recent and consecutive stewards again dividend XX% focus unchanged financially annual with from of the year, another for most and of at same XXth to strong to long-standing strategy. for solutions our approach main on all, our we increase a nutritional increase announced strong This year All our of $X.XX year-over-year.
fourth $XX we of quarter of at the an than of the delivered $XX an with margin basis up Now million, earnings net higher an year, EBITDA revenues EBITDA increase Consolidated quarter and income of closed the quarter the we X.X% quarterly morning, higher prior was XXX prior of million, were points million, GAAP This increase record of versus prior fourth adjusted quarter. operations adjusted quarter XX.X%, from year XX.X% XX.X% for regarding from year. fourth which $XXX XX%. the reported consolidated by XXXX. record the
basis, on income $XX to our $X.XX per to increase earnings net the XX.X% of quarterly adjusted net fourth translated us. quarter diluted Overall, or up million, which, an $X.XX net XX.X% prior record said translated very quarter capped basis, GAAP were off share. of strong earnings On per strong This another for which year earlier, I to adjusted compared year, year. from share prior Balchem, diluted an as a the for $X.XX another
back go in detail. a through for results more company going business to I'm the turn financial and for of our now little segments results the to to the over call consolidated fourth quarter Martin the each